Recommendations for severe hypertriglyceridemia treatment, are there new strategies?

Current Vascular Pharmacology

Volumn 12, Issue 4, 2014, Pages 598-616

  Filippatos, Theodosios D ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cardiovascular risk; Fibrates; Lipoprotein lipase; Niacin; Omega 3; Orlistat; Plasmapheresis; Severe hypertriglyceridemia

Indexed keywords

EZETIMIBE; FENOFIBRATE; FENOFIBRIC ACID; GEMFIBROZIL; PLACEBO; PRAVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; LACTONE; NICOTINIC ACID; OMEGA 3 FATTY ACID; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; GENE THERAPY; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; NONHUMAN; REVIEW; ALGORITHM; APHERESIS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIET THERAPY; LIFESTYLE; LOW FAT DIET; PRACTICE GUIDELINE; SEVERITY OF ILLNESS INDEX;

ALGORITHMS; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; DIET, FAT-RESTRICTED; FATTY ACIDS, OMEGA-3; FIBRIC ACIDS; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; LACTONES; LIFE STYLE; NIACIN; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 84904731851     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990133     Document Type: Review

References (410)

1. Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of severe (500 to 2, 000 mg/dl) hypertriglyceridemia in United States adults. Am J Cardiol 2011; 107: 891-7.
2. Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidaemias and hyperlipoprote-inaemias. Bull World Health Organ 1970; 43: 891-915.
3. Johansen CT, Hegele RA. Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol 2011; 22: 247-53.
4. Hu Y, Liu W, Huang R, Zhang X. A systematic review and metaanalysis of the relationship between lipoprotein lipase Asn291Ser variant and diseases. J Lipid Res 2006; 47: 1908-14.
5. Otarod JK, Goldberg IJ. Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr Atheroscler Rep 2004; 6: 335-42.
6. Chadarevian R, Foubert L, Beucler I, et al. Lipoprotein lipase activity and common gene variants in severely hypertriglyceridemic patients with and without diabetes. Horm Res 2003; 60: 61-7.
7. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 2009; 297: E271-88.
8. Evans V, Kastelein JJ. Lipoprotein lipase deficiency--rare or common? Cardiovasc Drugs Ther 2002; 16: 283-7.
9. Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 2012; 61: 906-21.
10. Scheffer PG, Teerlink T, Dekker JM, et al. Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study. Clin Chem 2008; 54: 1325-30.
11. Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008; 114: 611-24.
12. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001; 12: 297-304.
13. Filippatos T, Tsimihodimos V, Kostapanos M, Kostara C. Small dense LDL cholesterol and apolipoproteins C-II and C-III in nondiabetic obese subjects with metabolic syndrome. Arc Med Sci 2008; 3: 263-9.
14. Nilsson SK, Heeren J, Olivecrona G, Merkel M. Apolipoprotein AV; a potent triglyceride reducer. Atherosclerosis 2011; 219: 15-21.
15. Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res 2011; 52: 189-206.
16. Dergunov AD. Apolipoprotein e structure and substrate and receptor-binding activities of triglyceride-rich human plasma lipoproteins in normo-and hypertriglyceridemia. Biochemistry (Mosc) 2004; 69: 720-37.
17. Dergunov AD. Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: mechanistic and clinical studies. Biomed Pharmacother 2011; 65: 597-603.
18. Liberopoulos E, Miltiadous G, Hatzivassiliou M, et al. Apolipoprotein E polymorphism in northwestern Greece: frequency and effect on lipid parameters. Ann Clin Lab Sci 2004; 34: 347-54.
19. Liberopoulos E, Siamopoulos K, Elisaf M. Apolipoprotein E and renal disease. Am J Kidney Dis 2004; 43: 223-33.
20. Lloret Linares C, Pelletier AL, Czernichow S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008; 37: 13-2.
21. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007; 176: 1113-20.
22. Valdivielso P, Sanchez-Chaparro MA, Calvo-Bonacho E, et al. Association of moderate and severe hypertriglyceridemia with obesity, diabetes mellitus and vascular disease in the Spanish working population: results of the ICARIA study. Atherosclerosis 2009; 207: 573-8.
23. Neil HA, Cooper J, Betteridge DJ, et al. All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study. Atherosclerosis 2010; 211: 618-23.
24. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-8.
25. Murad MH, Hazem A, Coto-Yglesias F, et al. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord 2012; 12: 2.
26. Kuklina EV, Keenan NL, Callaghan WM, Hong Y. Risk of cardiovascular mortality in relation to optimal low-density lipoprotein cholesterol combined with hypertriglyceridemia: is there a difference by gender? Ann Epidemiol 2011; 21: 807-14.
27. McBride P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep 2008; 10: 386-90.
28. Tsimihodimos V, Gazi I, Filippatos T, et al. Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia. Atherosclerosis 2010; 208: 506-11.
29. Gazi IF, Milionis HJ, Filippatos TD, et al. Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women. Diabetes Metab Res Rev 2008; 24: 223-30.
30. Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 2006; 55: 885-91.
31. Gazi IF, Filippatos TD, Tsimihodimos V, et al. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids 2006; 41: 647-54.
32. Viljoen A, Wierzbicki AS. Diagnosis and treatment of severe hypertriglyceridemia. Expert Rev Cardiovasc Ther 2012; 10: 505-14.
33. Sandhu S, Al-Sarraf A, Taraboanta C, Frohlich J, Francis GA. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis 2011; 10: 157.
34. Oh RC, Lanier JB. Management of hypertriglyceridemia. Am Fam Physician 2007; 75: 1365-71.
35. Pejic RN, Lee DT. Hypertriglyceridemia. J Am Board Fam Med 2006; 19: 310-6.
36. Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP. Primary and secondary hypertriglyceridaemia. Curr Drug Targets 2009; 10: 336-43.
37. Seneff S, Wainwright G, Mascitelli L. Is the metabolic syndrome caused by a high fructose, and relatively low fat, low cholesterol diet? Arch Med Sci 2011; 7: 8-20.
38. Pavlidis AN, Kolovou GD, Anagnostopoulou KK, Petrou PC, Cokkinos DV. Postprandial metabolic heterogeneity in men with primary dyslipidaemia. Arch Med Sci 2010; 6: 879-86.
39. Subramanian S, Chait A. Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta 2012; 1821: 819-25.
40. Kumar V, Madhu SV, Singh G, Gambhir JK. Post-prandial hypertriglyceridemia in patients with type 2 diabetes mellitus with and without macrovascular disease. J Assoc Physicians India 2010; 58: 603-7.
41. Reneland R, Alvarez E, Andersson PE, Haenni A, Byberg L, Lithell H. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 2000; 14: 175-80.
42. Boquist S, Ruotolo G, Hellenius ML, Danell-Toverud K, Karpe F, Hamsten A. Effects of a cardioselective beta-blocker on postprandial triglyceride-rich lipoproteins, low density lipoprotein particle size and glucose-insulin homeostasis in middle-aged men with modestly increased cardiovascular risk. Atherosclerosis 1998; 137: 391-400.
43. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-74.
44. Spence JD, Huff M, Barnett PA. Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison. Can J Clin Pharmacol 2000; 7: 32-7.
45. Zane LT, Leyden WA, Marqueling AL, Manos MM. A populationbased analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006; 142: 1016-22.
46. Flynn WJ, Freeman PG, Wickboldt LG. Pancreatitis associated with isotretinoin-induced hypertriglyceridemia. Ann Intern Med 1987; 107: 63.
47. Gupta S, Tandon VR, Kapoor B, Gupta A, Gupta GD, Khajuria V. Effects of tamoxifen therapy on plasma lipid profile in patients of breast cancer. J Assoc Physicians India 2006; 54: 183-6.
48. Kohen I, Manu P. Rapidly worsening hypertriglyceridemia during treatment with risperidone. Am J Ther 2010; 17: 216-8.
49. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008; 101: 273-86.
50. Nagamine T. Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia. Intern Med 2008; 47: 181-2.
51. Pollono EN, Lopez-Olivo MA, Lopez JA, Suarez-Almazor ME. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010; 29: 947-55.
52. Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006; 33: 921-3.
53. Gazi IF, Apostolou FA, Liberopoulos EN, et al. Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein. Lipids 2011; 46: 953-60.
54. Jialal I, Amess W, Kaur M. Management of hypertriglyceridemia in the diabetic patient. Curr Diab Rep 2010; 10: 316-20.
55. Manfredini F, D'Addato S, Laghi L, et al. Influence of lifestyle measures on hypertriglyceridaemia. Curr Drug Targets 2009; 10: 344-55.
56. Barylski M, Malyszko J, Rysz J, Mysliwiec M, Banach M. Lipids, blood pressure, kidney-what was new in 2011? Arch Med Sci 2011; 7: 1055-66.
57. Mark L, Paragh G, Karadi I, Reiber I, Pados G, Kiss Z. An attempt to make lipid-lowering therapy more effective in Hungary. The results of MULTI GAP 2010 and the PLUS Program. Arch Med Sci 2011; 7: 760-6.
58. Katsiki N, Mikhailidis DP, Athyros VG, Hatzitolios AI, Karagiannis A, Banach M. Are we getting to lipid targets in real life? Arch Med Sci 2010; 6: 639-41.
59. Hession M, Rolland C, Kulkarni U, Wise A, Broom J. Systematic review of randomized controlled trials of low-carbohydrate vs. low-fat/low-calorie diets in the management of obesity and its comorbidities. Obes Rev 2009; 10: 36-50.
60. Horton ES. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. Obesity (Silver Spring) 2009; 17 Suppl 3: S43-8.
61. Seifalian AM, Filippatos TD, Joshi J, Mikhailidis DP. Obesity and arterial compliance alterations. Curr Vasc Pharmacol 2010; 8: 155-68.
62. Weeke P, Andersson C, Fosbol EL, et al. The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus-an analysis from the SCOUT lead-in period. BMC Endocr Disord 2010; 10: 3.
63. Filippatos TD, Elisaf MS. Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol 2010; 2: 139-42.
64. Madsen EL, Bruun JM, Skogstrand K, Hougaard DM, Christiansen T, Richelsen B. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects. Metabolism 2009; 58: 946-53.
65. Miyaki A, Maeda S, Yoshizawa M, et al. Effect of weight reduction with dietary intervention on arterial distensibility and endothelial function in obese men. Angiology 2009; 60: 351-7.
66. Tzotzas T, Filippatos TD, Triantos A, Bruckert E, Tselepis AD, Kiortsis DN. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr Metab Cardiovasc Dis 2008; 18: 477-82.
67. Florentin M, Liberopoulos EN, Filippatos TD, et al. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin Pharmacother 2008; 9: 2741-50.
68. Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomized study. Nutr Metab Cardiovasc Dis 2008; 18: 207-10.
69. Nakou E, Filippatos TD, Liberopoulos EN, et al. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother 2008; 9: 1629-39.
70. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21: 457-68.
71. Filippatos TD, Elisaf MS. Combination drug treatment in obese diabetic patients. World J Diabetes 2010; 1: 8-11.
72. Milionis HJ, Filippatos TD, Derdemezis CS, et al. Excess body weight and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. Eur J Neurol 2007; 14: 762-9.
73. Lim SS, Norman RJ, Clifton PM, Noakes M. The effect of comprehensive lifestyle intervention or metformin on obesity in young women. Nutr Metab Cardiovasc Dis 2011; 21: 261-8.
74. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomized ATTEMPT study. Arch Med Sci 2011; 7: 796-805.
75. Klop B, Wouter Jukema J, Rabelink TJ, Castro Cabezas M. A physician's guide for the management of hypertriglyceridemia: the etiology of hypertriglyceridemia determines treatment strategy. Panminerva Med 2012; 54: 91-103.
76. Shavelle RM, Paculdo DR, Strauss DJ, Kush SJ. Smoking habit and mortality: a meta-analysis. J Insur Med 2008; 40: 170-8.
77. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2008; 16: CD000165.
78. Banach M, Davidson M, Toth PP. Polish Lipid Association--a strong response to the problem of lipid disorders in Poland and Central and Eastern Europe. J Clin Lipidol 2012; 6: 105-7.
79. Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs 2008; 17: 1599-614.
80. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002; 18: 269-76.
81. Agouridis AP, Filippatos TD, Derdemezis CS, Mikhailidis DP, Elisaf MS. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des 2010; 16: 3401-16.
82. Spencer CM, Barradell LB. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs 1996; 51: 982-1018.
83. Sorisky A, Ooi TC, Simo IE, Meuffels M, Hindmarsh JT, Nair R. Change in composition of high density lipoprotein during gemfibrozil therapy. Atherosclerosis 1987; 67: 181-9.
84. Kahri J, Vuorinen-Markkola H, Tilly-Kiesi M, Lahdenpera S, Taskinen MR. Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity. Atherosclerosis 1993; 102: 79-89.
85. Gnasso A, Lehner B, Haberbosch W, Leiss O, von Bergmann K, Augustin J. Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects. Metabolism 1986; 35: 387-93.
86. Avellone G, Di Garbo V, Panno AV, Cordova R, Lepore R, Strano A. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia. Int Angiol 1988; 7: 270-7.
87. Gazi I, Tsimihodimos V, Filippatos TD, et al. LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis 2006; 5: 8.
88. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006; 113: 1556-63.
89. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004; 66: 1123-30.
90. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285: 1585-91.
91. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8.
92. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
93. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34: 155-62.
94. Dixon DL, Williams VG. Interaction between gemfibrozil and warfarin: case report and review of the literature. Pharmacotherapy 2009; 29: 744-8.
95. Love BL, Kehr H, Olin JL. Hypertriglyceridaemia-induced acute pancreatitis due to patient non-compliance. J Clin Pharm Ther 2009; 34: 363-7.
96. Ruman J, Brenner S, Sauer MV. Severe hypertriglyceridemia and pancreatitis following hormone replacement prior to cryothaw transfer. J Assist Reprod Genet 2002; 19: 94-7.
97. Jabbar MA, Zuhri-Yafi MI, Larrea J. Insulin therapy for a nondiabetic patient with severe hypertriglyceridemia. J Am Coll Nutr 1998; 17: 458-61.
98. Leaf DA, Connor WE, Illingworth DR, Bacon SP, Sexton G. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. JAMA 1989; 262: 3154-60.
99. Stein JH, Rosenson RS. Treatment of severe hypertriglyceridemia lowers plasma viscosity. Atherosclerosis 1998; 137: 401-5.
100. Roederer G, Xhignesse M, Davignon J. Eruptive and tuberoeruptive xanthomas of the skin arising on sites of prior injury. Two case reports. JAMA 1988; 260: 1282-3.
101. Elisaf MS, Dardamanis MA, Papagalanis ND, Siamopoulos KC. Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil. Scand J Urol Nephrol 1993; 27: 101-8.
102. Glueck CJ, Lang J, Hamer T, Tracy T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994; 123: 59-64.
103. Goldenberg NM, Wang P, Glueck CJ. An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. Clin Chim Acta 2003; 332: 11-9.
104. Jiang JT, Xu N, Zhang XY, Wu CP. Lipids changes in liver cancer. J Zhejiang Univ Sci B 2007; 8: 398-409.
105. Filippatos TD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP. Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev 2009; 35: 175-84.
106. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009; 181: 1998-2006.
107. Filippatos TD, Milionis HJ, Elisaf MS. Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol 2005; 75: 449-60.
108. Alagozlu H, Cindoruk M, Unal S. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. Clin Drug Investig 2006; 26: 297-302.
109. Sakhri J, Ben Salem C, Harbi H, Fathallah N, Ltaief R. Severe acute pancreatitis due to tamoxifen-induced hypertriglyceridemia with positive rechallenge. JOP 2010; 11: 382-4.
110. Santeufemia DA, Capobianco G, Dessole S, et al. Tamoxifen induced severe hypertriglyceridemia in a male patient with breast carcinoma. Breast J 2009; 15: 675-6.
111. Milionis HJ, Liberopoulos EN, Elisaf MS. Tamoxifen-induced hypertriglyceridemia in association with diabetes mellitus. Diabetes Metab 2001; 27: 160-3.
112. Elisaf M, Bairaktari E, Pavlidis N. The influence of tamoxifen on serum triglycerides. Breast 2000; 9: 238.
113. Elisaf MS, Nakou K, Liamis G, Pavlidis NA. Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol 2000; 11: 1067-9.
114. Wong SF, Jakowatz JG, Taheri R. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma. Ann Pharmacother 2004; 38: 1655-9.
115. Junghans V, Runger TM. Hypertriglyceridaemia following adjuvant interferon-alpha treatment in two patients with malignant melanoma. Br J Dermatol 1999; 140: 183-4.
116. Athanasiadis I, Kies MS, Miller M, et al. Phase II study of alltrans-retinoic acid and alpha-interferon in patients with advanced non-small cell lung cancer. Clin Cancer Res 1995; 1: 973-9.
117. Wong SF, Jakowatz JG, Taheri R. Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma. Clin Ther 2005; 27: 1942-8.
118. Yasar HY, Ertugrul O. Clomiphene citrate-induced severe hypertriglyceridemia. Fertil Steril 2009; 92: 396 e7-8.
119. http://www. camberpharma. com/uploads/userfiles/inserts/Gemfib rozil_Insert. pdf Accessed at 22-6-2012.
120. Fitzgerald JE, Petrere JA, de la Iglesia FA. Experimental studies on reproduction with the lipid-regulating agent gemfibrozil. Fundam Appl Toxicol 1987; 8: 454-64.
121. Tsai EC, Brown JA, Veldee MY, Anderson GJ, Chait A, Brunzell JD. Potential of essential fatty acid deficiency with extremely low fat diet in lipoprotein lipase deficiency during pregnancy: A case report. BMC Pregnancy Childbirth 2004; 4: 27.
122. Al-Shali K, Wang J, Fellows F, Huff MW, Wolfe BM, Hegele RA. Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase. Clin Biochem 2002; 35: 125-30.
123. Morse AN, Whitaker MD. Successful pregnancy in a woman with lipoatrophic diabetes mellitus. A case report. J Reprod Med 2000; 45: 850-2.
124. Perrone G, Critelli C. Severe hypertriglyceridemia in pregnancy. A clinical case report. Minerva Ginecol 1996; 48: 573-6.
125. Keilson LM, Vary CP, Sprecher DL, Renfrew R. Hyperlipidemia and pancreatitis during pregnancy in two sisters with a mutation in the lipoprotein lipase gene. Ann Intern Med 1996; 124: 425-8.
126. Saadi HF, Kurlander DJ, Erkins JM, Hoogwerf BJ. Severe hypertriglyceridemia and acute pancreatitis during pregnancy: treatment with gemfibrozil. Endocr Pract 1999; 5: 33-6.
127. Todd PA, Ward A. Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs 1988; 36: 314-39.
128. Milionis HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Curr Med Res Opin 2000; 16: 21-32.
129. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, Mikhailidis DP, Elisaf MS. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005; 3: 87-98.
130. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 366: 1849-61.
131. Tziomalos K, Athyros VG. Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. Int J Nanomedicine 2006; 1: 129-47.
132. Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk 1999; 6: 113-6.
133. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 1994; 154: 441-9.
134. Sharpe M, Ormrod D, Jarvis B. Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels. Am J Cardiovasc Drugs 2002; 2: 125-32.
135. Rosenson RS. Fenofibrate reduces lipoprotein associated phospho-lipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J 2008; 155: 499 e9-16.
136. Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH. Atorvastatin and fenofibrate have comparable effects on VLDLapolipoprotein C-III kinetics in men with the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 1831-7.
137. Hamilton SJ, Chew GT, Davis TM, Watts GF. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients. Clin Sci (Lond) 2010; 118: 607-15.
138. Genest J, Jr., Nguyen NH, Theroux P, Davignon J, Cohn JS. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. J Cardiovasc Pharmacol 2000; 35: 164-72.
139. Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring) 2009; 17: 504-9.
140. Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 2010; 95: 829-36.
141. Anderlova K, Dolezalova R, Housova J, et al. Influence of PPARalpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiol Res 2007; 56: 579-86.
142. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009; 32: 493-8.
143. Sacks FM. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol 2008; 102: 34L-40L.
144. Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomized controlled trial. Lancet 2009; 373: 1780-8.
145. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007; 370: 1687-97.
146. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Fibrateassociated adverse effects beyond muscle and liver toxicity. Curr Pharm Des 2008; 14: 574-87.
147. Tsimihodimos V, Kakafika A, Elisaf M. Fibrate treatment can increase serum creatinine levels. Nephrol Dial Transplant 2001; 16: 1301.
148. Tsimihodimos V, Bairaktari E, Elisaf M. Fibrate-induced increase in serum urea and creatinine levels. Nephrol Dial Transplant 2002; 17: 682.
149. Tsimihodimos V, Miltiadous G, Bairaktari E, Elisaf M. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol 2002; 57: 407-8.
150. Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 2004; 3: 101-11.
151. Luc G, Jacob N, Bouly M, Fruchart JC, Staels B, Giral P. Fenofibrate increases homocystinemia through a PPARalphamediated mechanism. J Cardiovasc Pharmacol 2004; 43: 452-3.
152. Attridge RL, Linn WD, Ryan L, Koeller J, Frei CR. Evaluation of the incidence and risk factors for development of fenofibrateassociated nephrotoxicity. J Clin Lipidol 2012; 6: 19-26.
153. Ting RD, Keech AC, Drury PL, et al. Benefits and safety of longterm fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care 2012; 35: 218-25.
154. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009; 54: 585-94.
155. Roth EM, Bays HE, Forker AD, et al. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects. J Cardiovasc Pharmacol 2009; 54: 196-203.
156. Cicero AF, Derosa G, Miconi A, Laghi L, Nascetti S, Gaddi A. Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10? Biofactors 2005; 23: 7-14.
157. Zeman M, Zak A, Vecka M, Tvrzicka E, Pisarikova A, Stankova B. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. J Nutr Biochem 2006; 17: 379-84.
158. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des 2009; 15: 490-516.
159. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005; 21: 1997-2006.
160. Filippatos TD, Tsimihodimos V, Kostapanos M, et al. Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome. Arch Med Sci 2008; 4: 263-9.
161. Kostapanos MS, Milionis HJ, Filippatos TD, et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 2007; 29: 1403-14.
162. Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense lowdensity lipoprotein phenotype. Circulation 2010; 121: 1722-34.
163. Filippatos T, Tsimihodimos V, Kostapanos M, et al. Analysis of the 6-month effect of orlistat, alone or in combination with fenofibrate, administration on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. J Clin Lipidol 2008; 2: 279-84.
164. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007; 7: 53-72.
165. Rizzo M, Pernice V, Frasheri A, et al. Small, dense low-density lipoproteins (LDL) are predictors of cardio-and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocrinol (Oxf) 2009; 70: 870-5.
166. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009; 1791: 327-38.
167. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 2094-9.
168. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005; 51: 2264-73.
169. Elisaf M, Tselepis AD. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol 2003; 66: 2069-73.
170. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007; 193: 428-37.
171. Lagos KG, Filippatos TD, Tsimihodimos V, et al. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids 2009; 44: 9-16.
172. Filippatos TD, Liberopoulos EN, Kostapanos M, et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 2008; 10: 476-83.
173. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 2010; 8: 12-28.
174. Filippatos TD, Tsimihodimos V, Derdemezis CS, et al. Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile. Nutr Metab Cardiovasc Dis 2011; 23: 330-6.
175. Kostapanos MS, Derdemezis CS, Filippatos TD, et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008; 578: 249-52.
176. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colonyenhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007; 30: 323-6.
177. Derdemezis C, Filippatos T, Tselepis A, Mikhailidis D, Elisaf M. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opin Pharmacother 2008; 9: 1829-37.
178. Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008; 38: 71-2.
179. Filippatos TD, Derdemezis CS, Georgoula M, Kiortsis DN, Tselepis AD, Elisaf MS. Fenofibrate and orlistat, alone or in combination, do not alter plasma visfatin levels in subjects with metabolic syndrome. J Med Sci Res 2007; 2: 9-10.
180. Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol 2003; 92: 794-7.
181. Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003; 91: 956-60.
182. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005; 95: 462-8.
183. Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003; 25: 459-71.
184. Corbelli JC, Bullano MF, Willey VJ, Cziraky MJ, Corbelli ME, Waugh W. Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy. Am J Cardiol 2002; 90: 1388-91.
185. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30: 1280-7.
186. Farnier M, Bortolini M, Salko T, et al. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol 2003; 91: 238-40.
187. May HT, Anderson JL, Pearson RR, et al. Comparison of Effects of Simvastatin Alone Versus Fenofibrate Alone Versus Simvastatin Plus Fenofibrate on Lipoprotein Subparticle Profiles in Diabetic Patients With Mixed Dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen Study). Am J Cardiol 2008; 101: 486-9.
188. Wierzbicki AS, Mikhailidis DP, Wray R. Drug treatment of combined hyperlipidemia. Am J Cardiovasc Drugs 2001; 1: 327-36.
189. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003; 19: 155-68.
190. Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99: 21i-33i.
191. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-74.
192. http://www. fda. gov/Drugs/DrugSafety/ucm278837. htm (accessed at 07/10/12).
193. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80: 608-13.
194. Franssen R, Vergeer M, Stroes ES, Kastelein JJ. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab 2009; 11: 89-94.
195. Kiortsis DN, Filippatos TD, Mikhailidis DP, Elisaf MS, Liberopoulos EN. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007; 195: 7-16.
196. Sweeney ME, Johnson RR. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 2007; 3: 441-50.
197. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23: 2183-92.
198. Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 2008; 24: 1919-29.
199. Nakou ES, Filippatos TD, Kiortsis DN, et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 2008; 9: 3151-8.
200. Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterolassociated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006; 10: 851-66.
201. Filippatos TD, Elisaf MS. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol 2011; 3: 265-7.
202. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007; 23: 1169-76.
203. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-26.
204. Simons LA, Symons J. Ezetimibe added to statin therapy (EASY study)-an evaluation by Australian general practitioners. Aust Fam Physician 2007; 36: 90-2.
205. Reckless JP, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract 2008; 62: 539-54.
206. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients. Am J Cardiol 2008; 101: 483-5.
207. Agouridis AP, Filippatos TD, Tsimihodimos V, Elisaf MS. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Rev Cardiovasc Ther 2011; 9: 355-66.
208. Nakou ES, Filippatos TD, Agouridis AP, Kostara C, Bairaktari ET, Elisaf MS. The effects of ezetimibe and/or orlistat on triglyceriderich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids 2010; 45: 445-50.
209. Shekhar Pandey A, Bissonnette S, Boukas S, Rampakakis E, Sampalis JS. Effectiveness and tolerability of ezetimibe coadministered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial. Arch Med Sci 2011; 7: 767-75.
210. Farnier M. Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia? Expert Opin Pharmacother 2007; 8: 1345-52.
211. Moon YS, Chun P, Chung S. Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia. Drugs Today (Barc) 2007; 43: 35-45.
212. Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. Am J Cardiovasc Drugs 2009; 9: 91-101.
213. Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26: 897-905.
214. McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006; 47: 1584-7.
215. Kumar SS, Lahey KA, Day A, LaHaye SA. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis 2009; 8: 56.
216. Tribble DL, Farnier M, Macdonell G, et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 2008; 57: 796-801.
217. Kosoglou T, Statkevich P, Fruchart JC, et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004; 20: 1197-207.
218. Javot L, Spaeth D, Scala-Bertola J, Gambier N, Petitpain N, Gillet P. Severe hypertriglyceridaemia during treatment with capecitabine. Br J Cancer 2011; 104: 1238-9.
219. Seminara P, Losanno T, Emiliani A, Manna G. Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect? Cardiology 2010; 116: 42-4.
220. Bar-Sela G, Haim N. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature. Cancer Chemother Pharmacol 2009; 63: 779-82.
221. Orphanos GS, Stavrou NG, Picolos MK. Hypertriglyceridemia: An underdiagnosed side effect of Capecitabine chemotherapy. Acta Oncol 2010; 49: 262-3.
222. Michie CO, Sakala M, Rivans I, Strachan MW, Clive S. The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. Br J Cancer 2010; 103: 617-21.
223. Filippatos TD. A review of time courses and predictors of lipid changes with fenofibric Acid-statin combination. Cardiovasc Drugs Ther 2012; 26: 245-55.
224. Chapman MJ. Pharmacology of fenofibrate. Am J Med 1987; 83: 21-5.
225. Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag 2010; 6: 525-39.
226. Trilipix [Package insert]. North Chicago, IL: Abbott Laboratories; 2009. Available from: http://www. trilipixpro. com/. Accessed on May 26, 2010.
227. Alagona P, Jr. Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vasc Health Risk Manag 2010; 6: 351-62.
228. Prueksaritanont T, Richards KM, Qiu Y, et al. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 2005; 22: 71-8.
229. Jones PH, Bays HE, Davidson MH, et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme. Clin Drug Investig 2008; 28: 625-34.
230. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009; 157: 195-203.
231. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009; 103: 515-22.
232. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009; 204: 208-15.
233. Roth EM, Rosenson RS, Carlson DM, et al. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia-a phase 3 study. Cardiovasc Drugs Ther 2010; 24: 421-8.
234. Roth EM, McKenney JM, Kelly MT, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. Am J Cardiovasc Drugs 2010; 10: 175-86.
235. Jones PH, Goldberg AC, Knapp HR, et al. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am Heart J 2010; 160: 759-66.
236. Bays H, Jones P, Mohiuddin S, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol 2008; 2: 426-35.
237. Kipnes MS, Roth EM, Rhyne JM, et al. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. Clin Drug Investig 2010; 30: 51-61.
238. Bays HE, Roth EM, McKenney JM, et al. The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. Diabetes Care 2010; 33: 2113-6.
239. Jones PH, Cusi K, Davidson MH, et al. Efficacy and safety of fenofibric acid co-administered with low-or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs 2010; 10: 73-84.
240. Pepine CJ, Jacobson TA, Carlson DM, et al. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. Clin Cardiol 2010; 33: 609-19.
241. Gazi I, Liberopoulos EN, Saougos VG, Elisaf M. Beneficial effects of omega-3 fatty acids: the current evidence. Hellenic J Cardiol 2006; 47: 223-31.
242. Lu G, Windsor SL, Harris WS. Omega-3 fatty acids alter lipoprotein subfraction distributions and the in vitroconversion of very low density lipoproteins to low density lipoproteins. J Nutr Biochem 1999; 10: 151-8.
243. Calabresi L, Donati D, Pazzucconi F, Sirtori CR, Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 2000; 148: 387-96.
244. Abel S, Gelderblom WC, Smuts CM, Kruger M. Thresholds and kinetics of fatty acid replacement in different cellular compartments in rat liver as a function of dietary n-6/n-3 fatty acid content. Prostaglandins Leukot Essent Fatty Acids 1997; 56: 29-39.
245. Papazafiropoulou AK, Kardara MS, Pappas SI. Pleiotropic effects of omega-3 fatty acids. Recent Pat Endocr Metab Immune Drug Discov 2012; 6: 40-6.
246. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005; 165: 725-30.
247. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009; 32: 365-72.
248. Zhao YT, Chen Q, Sun YX, et al. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Ann Med 2009; 41: 301-10.
249. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447-55.
250. Mariscalco G, Sarzi Braga S, Banach M, et al. Preoperative n-3 polyunsatured fatty acids are associated with a decrease in the incidence of early atrial fibrillation following cardiac surgery. Angiology 2010; 61: 643-50.
251. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a metaanalysis of randomized controlled trials. Am J Med 2002; 112: 298-304.
252. Yzebe D, Lievre M. Fish oils in the care of coronary heart disease patients: a meta-analysis of randomized controlled trials. Fundam Clin Pharmacol 2004; 18: 581-92.
253. Chen Q, Cheng LQ, Xiao TH, et al. Effects of omega-3 fatty acid for sudden cardiac death prevention in patients with cardiovascular disease: a contemporary meta-analysis of randomized, controlled trials. Cardiovasc Drugs Ther 2011; 25: 259-65.
254. Kwak SM, Myung SK, Lee YJ, Seo HG. Efficacy of Omega-3 Fatty Acid Supplements (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized, Double-blind, Placebo-Controlled Trials. Arch Intern Med 2012; 172: 686-94.
255. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65: 1645S-54S.
256. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997; 4: 385-91.
257. Stalenhoef AF, de Graaf J, Wittekoek ME, Bredie SJ, Demacker PN, Kastelein JJ. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis 2000; 153: 129-38.
258. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006; 189: 19-30.
259. Peters BS, Wierzbicki AS, Moyle G, Nair D, Brockmeyer N. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial. Clin Ther 2012; 34: 67-76.
260. Hauenschild A, Bretzel RG, Schnell-Kretschmer H, Kloer HU, Hardt PD, Ewald N. Successful treatment of severe hypertriglyceridemia with a formula diet rich in omega-3 fatty acids and medium-chain triglycerides. Ann Nutr Metab 2010; 56: 170-5.
261. Cicero AF, Derosa G, Miconi A, Laghi L, Nascetti S, Gaddi A. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. Biomed Pharmacother 2005; 59: 312-7.
262. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 2008; 48: 79-106.
263. Wanders D, Judd RL. Future of GPR109A agonists in the treatment of dyslipidaemia. Diabetes Obes Metab 2011; 13: 685-91.
264. Villines TC, Kim AS, Gore RS, Taylor AJ. Niacin: the evidence, clinical use, and future directions. Curr Atheroscler Rep 2012; 14: 49-59.
265. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008; 101: 20B-6B.
266. Hernandez C, Molusky M, Li Y, Li S, Lin JD. Regulation of hepatic ApoC3 expression by PGC-1beta mediates hypolipidemic effect of nicotinic acid. Cell Metab 2010; 12: 411-9.
267. Tenenbaum A, Fisman EZ, Motro M, Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006; 5: 20.
268. Milionis HJ, Filippatos TD, Loukas T, Bairaktari ET, Tselepis AD, Elisaf MS. Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis 2006; 187: 170-6.
269. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010; 126: 314-45.
270. Kei A, Elisaf M, Moutzouri E, Tsiara S, Liberopoulos E. Add-onStatin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study. Int J Hypertens 2011; 2011: 830434.
271. Florentin M, Liberopoulos EN, Kei A, Mikhailidis DP, Elisaf MS. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol 2011; 9: 385-400.
272. Kei A, Liberopoulos EN, Elisaf MS. What restricts the clinical use of nicotinic acid? Curr Vasc Pharmacol 2011; 9: 521-30.
273. Chen F, Maccubbin D, Yan L, et al. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol 2012; In press.
274. McKenney J, Bays H, Koren M, et al. Safety of extended-release niacin/laropiprant in patients with dyslipidemia. J Clin Lipidol 2010; 4: 105-12 e1.
275. Yadav R, France M, Younis N, et al. Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety. Expert Opin Pharmacother 2012; 13: 1345-62.
276. Nicotinic acid + laropiprant. Laropiprant adds its own adverse effects. Prescrire Int 2010; 19: 9-11.
277. Thakkar RB, Kashyap ML, Lewin AJ, Krause SL, Jiang P, Padley RJ. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs 2009; 9: 69-79.
278. Yadav R, Kwok S, Ammori BJ, Issa B, Soran H. Safety and tolerability of extended-release niacin with laropiprant. Expert Opin Drug Saf 2012; 11: 151-9.
279. Kei A, Elisaf MS. Nicotinic acid: clinical considerations. Expert Opin Drug Saf 2012; 11: 551-64.
280. McKenney JM, McCormick LS, Weiss S, Koren M, Kafonek S, Black DM. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. Am J Med 1998; 104: 137-43.
281. Carlson LA, Froberg S, Oro L. A case of massive hypertriglyceridemia corrected by nicotinic acid or nicotinamide therapy. Atherosclerosis 1972; 16: 359-68.
282. Carlson LA, Wahlberg G. Relative increase in apolipoprotein CII content of VLDL and chylomicrons in a case with massive type V hyperlipoproteinaemia by nicotinic acid treatment. Atherosclerosis 1978; 31: 77-84.
283. Carlson LA, Eriksson I, Walldius G. A case of massive hypertriglyceridaemia and impaired fatty acid incorporation into adipose tissue glycerides (FIAT), both corrected by nicotinic acid. Acta Med Scand 1973; 194: 363-9.
284. Insull W, Jr., Toth PP, Superko HR, et al. Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. Vasc Health Risk Manag 2010; 6: 1065-75.
285. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extendedrelease niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007; 192: 432-7.
286. Van JT, Pan J, Wasty T, Chan E, Wu X, Charles MA. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am J Cardiol 2002; 89: 1306-8.
287. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 2008; 101: 1428-36.
288. Capuzzi DM, Morgan JM, Carey CM, et al. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. Prev Cardiol 2004; 7: 176-81.
289. Bays H, Giezek H, McKenney JM, O'Neill EA, Tershakovec AM. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metab Syndr Relat Disord 2012; 10: 260-6.
290. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
291. Podrez EA. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol Physiol 2010; 37: 719-25.
292. Andrews KL, Moore XL, Chin-Dusting JP. Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium. Clin Exp Pharmacol Physiol 2010; 37: 736-42.
293. Meurs I, Van Eck M, Van Berkel TJ. High-density lipoprotein: key molecule in cholesterol efflux and the prevention of atherosclerosis. Curr Pharm Des 2010; 16: 1445-67.
294. Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) 2009; 116: 87-98.
295. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-atherogenic properties of HDL. J Lipid Res 2009; 50 Suppl: S195-200.
296. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011; 17: 594-603.
297. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011; 22: 176-85.
298. Lund-Katz S, Phillips MC. High density lipoprotein structurefunction and role in reverse cholesterol transport. Subcell Biochem 2010; 51: 183-227.
299. Siri-Tarino PW. Effects of diet on high-density lipoprotein cholesterol. Curr Atheroscler Rep 2011; 13: 453-60.
300. Kostapanos MS, Milionis HJ, Filippatos TD, et al. Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther 2009; 14: 5-13.
301. Ansell BJ, Navab M, Hama S, et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-6.
302. Vazquez E, Sethi AA, Freeman L, et al. High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese women. Am J Cardiol 2012; 109: 527-32.
303. Sorrentino SA, Besler C, Rohrer L, et al. Endothelialvasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010; 121: 110-22.
304. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51: 314-24.
305. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011; 8: 222-32.
306. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. Available at http//www. clinicaltrials. gov/show/NCT00461630. Accessed at 10-6-2012.
307. Balasubramanyam A, Coraza I, Smith EO, et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive, " a randomized, controlled trial. J Clin Endocrinol Metab 2011; 96: 2236-47.
308. Spencer GA, Wirebaugh S, Whitney EJ. Effect of a combination of gemfibrozil and niacin on lipid levels. J Clin Pharmacol 1996; 36: 696-700.
309. Krasuski RA, Devendra GP, Cater G, Whitney EJ. The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study. Am J Med Sci 2011; 341: 378-82.
310. Superko HR, Garrett BC, King SB, 3rd, Momary KM, Chronos NA, Wood PD. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia. Am J Cardiol 2009; 103: 387-92.
311. Qandil AM, Rezigue MM, Tashtoush BM. Synthesis, characterization and in vitrohydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. Eur J Pharm Sci 2011; 43: 99-108.
312. Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 2008; 4: 341-53.
313. Filippatos TD, Mikhailidis DP. Statins and heart failure. Angiology 2008; 59: 58S-61S.
314. Milionis HJ, Rizos E, Kostapanos M, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006; 22: 1123-31.
315. Milionis HJ, Gazi IF, Filippatos TD, et al. Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering? Angiology 2005; 56: 585-92.
316. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009; 15: MS1-5.
317. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81: 66B-9B.
318. Agouridis AP, Tsimihodimos V, Filippatos TD, Tselepis AD, Elisaf MS. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids 2011; 46: 521-8.
319. Agouridis AP, Tsimihodimos V, Filippatos TD, et al. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother 2011; 12: 2605-11.
320. Falasca K, Ucciferri C, Mancino P, Pizzigallo E, Calza L, Vecchiet J. Severe HIV-associated hypertriglyceridaemia treated with rosuvastatin plus omega-3 fatty acids. Int J STD AIDS 2009; 20: 580-1.
321. Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother 2011; 12: 1945-58.
322. Stefanutti C, Bucci A, Di Giacomo S, et al. Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia. Clin Drug Investig 2004; 24: 465-77.
323. Huang XS, Zhao SP, Bai L, Hu M, Zhao W, Zhang Q. Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha. Br J Pharmacol 2009; 158: 706-12.
324. Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther 2009; 31: 2824-38.
325. Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004; 64: 137-51.
326. Badawy O, Wierzbicki AS, Hilton R. Combination fibrate-statin therapy for the treatment of severe hypertriglyceridaemia in renal disease. Int J Clin Pract 2003; 57: 249-51.
327. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116: 408-16.
328. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007; 99: 3C-18C.
329. Taher TH, Dzavik V, Reteff EM, Pearson GJ, Woloschuk BL, Francis GA. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol 2002; 89: 390-4.
330. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90.
331. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120-2.
332. Filippatos T, Derdemezis C, Elisaf M. Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors. Clin Lipidol 2009; 4: 331-41.
333. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005; 31: 15-22.
334. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4: 49-55.
335. Petrogiannopoulos C, Kalogeropoulos S, Latsios GS, Hartzoulakis G, Kalogeropoulos G, Zaharof A. Orlistat use in overweight women with mild hypercholesterolemia. Int J Clin Pharmacol Res 2002; 22: 85-8.
336. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003; 25: 1107-22.
337. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-94.
338. Naumann E, Plat J, Kester AD, Mensink RP. The baseline serum lipoprotein profile is related to plant stanol induced changes in serum lipoprotein cholesterol and triacylglycerol concentrations. J Am Coll Nutr 2008; 27: 117-26.
339. Derdemezis CS, Filippatos TD, Mikhailidis DP, Elisaf MS. Review article: effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering. J Cardiovasc Pharmacol Ther 2010; 15: 120-34.
340. Tan KC, Tso AW, Tam SC, Pang RW, Lam KS. Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus. Diabet Med 2002; 19: 944-8.
341. Reitsma JB, Castro Cabezas M, de Bruin TW, Erkelens DW. Relationship between improved postprandial lipemia and lowdensity lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 1994; 43: 293-8.
342. Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. Am J Cardiol 2002; 89: 229-31.
343. Tzotzas T, Krassas GE, Bruckert E. Administration of orlistat in a patient with familial hyperchylomicronemia. Atherosclerosis 2002; 165: 185-6.
344. Tolentino MC, Ferenczi A, Ronen L, Poretsky L. Combination of gemfibrozil and orlistat for treatment of combined hyperlipidemia with predominant hypertriglyceridemia. Endocr Pract 2002; 8: 208-12.
345. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31: 53-65.
346. Ewald N, Kloer HU. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis. Clin Res Cardiol Suppl 2012; 7: 31-5.
347. Betteridge DJ, Bakowski M, Taylor KG, Reckless JP, de Silva SR, Galton DJ. Treatment of severe diabetic hypertriglyceridaemia by plasma exchange. Lancet 1978; 1: 1368.
348. Izquierdo-Ortiz MJ, Abaigar-Luquin P. Severe hypertrigly-ceridaemia. Treatment with plasmapheresis. Nefrologia 2012; 32: 417-8.
349. Stefanutti C, Di Giacomo S, Labbadia G. Timing clinical events in the treatment of pancreatitis and hypertriglyceridemia with therapeutic plasmapheresis. Transfus Apher Sci 2011; 45: 3-7.
350. Manrique Franco K, Sanchez-Vilar Burdiel O, Aragon Valera C, Sanchez Fernandez MS, Rovira Loscos A. [Plasmapheresis as treatment for severe hypertriglyceridemia]. Endocrinol Nutr 2011; 58: 319-20.
351. Hovland A, Hardersen R, Mollnes TE, Lappegard KT. Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia. JOP 2010; 11: 467-9.
352. Ewald N, Kloer HU. Severe hypertriglyceridemia: an indication for apheresis? Atheroscler Suppl 2009; 10: 49-52.
353. Hen K, Bogdanski P, Pupek-Musialik D. [Successful treatment of severe hypertriglyceridemia with plasmapheresis--case report]. Pol Merkur Lekarski 2009; 26: 62-4.
354. Kfoury-Baz EM, Nassar RA, Tanios RF, et al. Plasmapheresis in asparaginase-induced hypertriglyceridemia. Transfusion 2008; 48: 1227-30.
355. Iskandar SB, Olive KE. Plasmapheresis as an adjuvant therapy for hypertriglyceridemia-induced pancreatitis. Am J Med Sci 2004; 328: 290-4.
356. Routy JP, Smith GH, Blank DW, Gilfix BM. Plasmapheresis in the treatment of an acute pancreatitis due to protease inhibitor-induced hypertriglyceridemia. J Clin Apher 2001; 16: 157-9.
357. Ho KM, Yeo J. Plasmapheresis in the management of pancreatitis related to hypertriglyceridaemia. Anaesth Intensive Care 1999; 27: 117.
358. Ford P, Breheny F, Jenkins I. Plasmapheresis in the management of pancreatitis related to hypertriglyceridaemia. Anaesth Intensive Care 1998; 26: 598.
359. Piolot A, Nadler F, Cavallero E, Coquard JL, Jacotot B. Prevention of recurrent acute pancreatitis in patients with severe hypertriglyceridemia: value of regular plasmapheresis. Pancreas 1996; 13: 96-9.
360. Candrina R, Di Stefano O, Spandrio S, Giustina G. Doublefiltration plasmapheresis for hypertriglyceridemia. JAMA 1990; 263: 35.
361. Kyriakidis AV, Karydakis P, Neofytou N, et al. Plasmapheresis in the management of acute severe hyperlipidemic pancreatitis: report of 5 cases. Pancreatology 2005; 5: 201-4.
362. Kadikoylu G, Yukselen V, Yavasoglu I, Coskun A, Karaoglu AO, Bolaman Z. Emergent therapy with therapeutic plasma exchange in acute recurrent pancreatitis due to severe hypertriglyceridemia. Transfus Apher Sci 2010; 43: 285-9.
363. Gubensek J, Buturovic-Ponikvar J, Marn-Pernat A, et al. Treatment of hyperlipidemic acute pancreatitis with plasma exchange: a single-center experience. Ther Apher Dial 2009; 13: 314-7.
364. Yeh JH, Chen JH, Chiu HC. Plasmapheresis for hyperlipidemic pancreatitis. J Clin Apher 2003; 18: 181-5.
365. Stefanutti C, Di Giacomo S, Vivenzio A, et al. Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study. Artif Organs 2009; 33: 1096-102.
366. Kyriakidis AV, Raitsiou B, Sakagianni A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion 2006; 73: 259-64.
367. Lennertz A, Parhofer KG, Samtleben W, Bosch T. Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. Ther Apher 1999; 3: 227-33.
368. Yeh JH, Lee MF, Chiu HC. Plasmapheresis for severe lipemia: comparison of serum-lipid clearance rates for the plasma-exchange and double-filtration variants. J Clin Apher 2003; 18: 32-6.
369. Giannini G, Valbonesi M, Morelli F, et al. Hypertriglyceridemia: apheretic treatment. Int J Artif Organs 2005; 28: 1018-24.
370. Chen JH, Yeh JH, Lai HW, Liao CS. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol 2004; 10: 2272-4.
371. Solano-Paez P, Villegas JA, Colomer I, Gutierrez MD, FernandezTeijeiro A. L-Asparaginase and steroids-associated hypertriglyceridemia successfully treated with plasmapheresis in a child with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2011; 33: e122-4.
372. Lutfi R, Huang J, Wong HR. Plasmapheresis to treat hypertriglyceridemia in a child with diabetic ketoacidosis and pancreatitis. Pediatrics 2012; 129: e195-8.
373. Altun D, Eren G, Cukurova Z, Hergunsel O, Yasar L. An alternative treatment in hypertriglyceridemia-induced acute pancreatitis in pregnancy: Plasmapheresis. J Anaesthesiol Clin Pharmacol 2012; 28: 252-4.
374. Ridola V, Buonuomo PS, Maurizi P, et al. Severe acute hypertriglyceridemia during acute lymphoblastic leukemia induction successfully treated with plasmapheresis. Pediatr Blood Cancer 2008; 50: 378-80.
375. Niro J, Sapin V, Constantin JM, et al. Management of gestational hypertriglyceridemia by plasmapheresis. Gynecol Obstet Fertil 2007; 35: 1133-5.
376. Exbrayat V, Morel J, De Filippis JP, Tourne G, Jospe R, Auboyer C. Hypertriglyceridemia-induced pancreatitis in pregnancy. A case report. Ann Fr Anesth Reanim 2007; 26: 677-9.
377. Schaefer EW, Leung A, Kravarusic J, Stone NJ. Management of severe hypertriglyceridemia in the hospital: A review. J Hosp Med 2012; 7: 431-8.
378. Poonuru S, Pathak SR, Vats HS, Pathak RD. Rapid reduction of severely elevated serum triglycerides with insulin infusion, gemfibrozil and niacin. Clin Med Res 2011; 9: 38-41.
379. Smith SR. Severe hypertriglyceridaemia responding to insulin and nicotinic acid therapy. Postgrad Med J 1981; 57: 511-5.
380. Lawson EB, Gottschalk M, Schiff DE. Insulin infusion to treat severe hypertriglyceridemia associated with pegaspargase therapy: a case report. J Pediatr Hematol Oncol 2011; 33: e83-6.
381. Twilla JD, Mancell J. Hypertriglyceridemia-induced acute pancreatitis treated with insulin and heparin. Am J Health Syst Pharm 2012; 69: 213-6.
382. Albahrani AI, Usher JJ, Marks E, Ranganath L, Shenkin A. Atypical presentation of a middle age male with severe hypertriglyceridaemia: a case report. J Med Case Rep 2007; 1: 51.
383. Weintraub MS, Charach G, Grosskopf I. Effects of fibric acid derivatives and metformin on postprandial lipemia. Atherosclerosis 1998; 141 Suppl 1: S71-5.
384. Chappuis B, Braun M, Stettler C, et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007; 23: 392-9.
385. Abbasi F, Lamendola C, Leary ET, Reaven GM. Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin-resistant smokers. Diabetes Obes Metab 2009; 11: 779-85.
386. Al Majali K, Cooper MB, Staels B, Luc G, Taskinen MR, Betteridge DJ. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 2006; 49: 527-37.
387. Ahren B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl 2008; 8-14.
388. Miura K, Kitahara Y, Yamagishi S. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats. Horm Metab Res 2010; 42: 731-5.
389. Tan M, Wai D, Chng CL, Hwang W. Acarbose is an effective treatment for severe hypertriglyceridemia secondary to lasparaginase and dexamethasone. Leuk Lymphoma 2012; 53: 1245-6.
390. Cole RP. Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis. Arch Intern Med 2009; 169: 1439-41.
391. Jain P, Rai RR, Udawat H, Nijhawan S, Mathur A. Insulin and heparin in treatment of hypertriglyceridemia-induced pancreatitis. World J Gastroenterol 2007; 13: 2642-3.
392. Alagozlu H, Cindoruk M, Karakan T, Unal S. Heparin and insulin in the treatment of hypertriglyceridemia-induced severe acute pancreatitis. Dig Dis Sci 2006; 51: 931-3.
393. Monga A, Arora A, Makkar RP, Gupta AK. Hypertriglyceridemiainduced acute pancreatitis--treatment with heparin and insulin. Indian J Gastroenterol 2003; 22: 102-3.
394. Jain D, Zimmerschied J. Heparin and Insulin for Hypertrigly-ceridemia-Induced Pancreatitis: Case Report. Sci World J 2009; 9: 1230-2.
395. Al Riyami NB, Frohlich J. Extreme hypertriglyceridemia following intravenous heparin infusion. Clin Biochem 2008; 41: 907-9.
396. Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG. Lipoprotein lipase during continuous heparin infusion: tissue stores become partially depleted. J Lab Clin Med 2001; 138: 206-13.
397. Nierman MC, Prinsen BH, Rip J, et al. Enhanced conversion of triglyceride-rich lipoproteins and increased low-density lipoprotein removal in LPLS447X carriers. Arterioscler Thromb Vasc Biol 2005; 25: 2410-5.
398. Burnett JR, Hooper AJ. Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. Curr Opin Mol Ther 2009; 11: 681-91.
399. Gaudet D, de Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler 2010; 11: 55-60.
400. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008; 28: 2303-4.
401. Shoulders CC, Shelness GS. Current biology of MTP: implications for selective inhibition. Curr Top Med Chem 2005; 5: 283-300.
402. Wierzbicki AS, Hardman T, Prince WT. Future challenges for microsomal transport protein inhibitors. Curr Vasc Pharmacol 2009; 7: 277-86.
403. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356: 148-56.
404. Rizzo M. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs 2010; 13: 103-11.
405. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5: 497-505.
406. Lomitapide. Am J Cardiovasc Drugs 2011; 11: 347-52.
407. Chandler CE, Wilder DE, Pettini JL, et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003; 44: 1887-901.
408. Holmberg R, Refai E, Hoog A, et al. Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc Natl Acad Sci USA 2011; 108: 10685-9.
409. Tran K, Wang Y, DeLong CJ, Cui Z, Yao Z. The assembly of very low density lipoproteins in rat hepatoma McA-RH7777 cells is inhibited by phospholipase A2 antagonists. J Biol Chem 2000; 275: 25023-30.
410. Ma W, Belisle SE, Mosier D, et al. 2009 pandemic H1N1 influenza virus causes disease and upregulation of genes related to inflammatory and immune responses, cell death, and lipid metabolism in pigs. J Virol 2011; 85: 11626-37.